Construction and Characterization of KRAS Immune Lipid Magnetic Balls for Colorectal Cancer Circulating Tumor Cells

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64(10):1637–1649. doi:10.1136/gutjnl-2014-30908626041752
   PubMed Web of Science ®Google Scholar
• Tzeng CW, Alola TA. Colorectal liver metastases. J Gastrointestinal Surg. 2013;17(1):195–201. doi:10.1007/s11605-012-2022-3
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Batth IS, Mitra A, Rood S, et al. CTC analysis: an update on technological progress. Translational Res. 2019;212:14–25. doi:10.1016/j.trsl.2019.07.003
   PubMed Web of Science ®Google Scholar
• Hao YX, Fu Q, Guo YY, et al. Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis. Onco Targets and Therapy. 2017;10:945–953. doi:10.2147/OTT.S123954
   PubMed Web of Science ®Google Scholar
• Buim M, Fanelli M, Souza VS, et al. Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. Cancer Biol Ther. 2015;16(9):1289–1295. doi:10.1080/15384047.2015.107099126252055
   PubMed Web of Science ®Google Scholar
• Liu DG, Xue L, Li J, et al. Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer. Cancer Biomark. 2018;22(3):417–426. doi:10.3233/CBM-17099529758927
   PubMed Web of Science ®Google Scholar
• Rugo HS, Cortes J, Awada A, et al. Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegolr. Clin Cancer Res. 2018;24(14):3348–3357. doi:10.1158/1078-0432.CCR-17-305929618616
   PubMed Web of Science ®Google Scholar
• Bahrami A, Hassanian SM, ShahidSales S, et al. Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. J Cell Physiol. 2018;233(3):2058–2066. doi:10.1002/jcp.2589028262927
   PubMed Web of Science ®Google Scholar
• Neuzillet C, Tijeras-raballand A, Mestier L, et al. MEK in cancer and cancer therapy. Pharmacol Ther. 2014;141(2):160–171. doi:10.1016/j.pharmthera.2013.10.00124121058
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Elez E, Argiles G, et al. Analysis of mutant allele fractions in driver genes in colorectal cancer-biological and clinical insights. Mol Oncol. 2017;11(9):1263–1272. doi:10.1002/1878-0261.1209928618197
   PubMed Web of Science ®Google Scholar
• Prieur A, Cappellini M, Habif G, et al. Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer. Clin Cancer Res. 2017;23(17):5267–5280. doi:10.1158/1078-0432.CCR-17-053328600477
   PubMed Web of Science ®Google Scholar
• Karmakar S, Kaushik G, Nimmakayala R, et al. MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention. Semin Cancer Biol. 2019;54:63–71. doi:10.1016/j.semcancer.2017.11.02029199014
   PubMed Web of Science ®Google Scholar
• Cavalloni G, Peraldoneia C, Sassi F, et al. Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. Bmc Cancer. 2016;16(1):90. doi:10.1186/s12885-016-2136-126868125
   PubMedGoogle Scholar
• Koo KH, Jeong WJ, Cho YH, et al. K-Ras stabilization by estrogen via PKCdelta is involved in endometrial tumorigenesis. Oncotarget. 2015;6(25):21328–21340. doi:10.18632/oncotarget.404926015399
   PubMedGoogle Scholar
• Liu R, Li J, Lai Y, et al. Hsa-miR-1 suppresses breast cancer development by down-regulating K-ras and long non-coding RNA MALAT1. Int J Biol Macromol. 2015;81:491–497. doi:10.1016/j.ijbiomac.2015.08.01626275461
   PubMed Web of Science ®Google Scholar
• Wang L, Zhao Y, Xiong Y, et al. K-ras mutation promotes ionizing radiation-induced invasion and migration of lung cancer in part via the Cathepsin L/CUX1 pathway. Exp Cell Res. 2018;362(2):424–435. doi:10.1016/j.yexcr.2017.12.00629246726
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Köhne CH, Ciardiello F, et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer. 2015;51(10):1243–1252. doi:10.1016/j.ejca.2015.04.00725937522
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lenz HJ, Köhne CH, et al. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer. J Clin Oncol. 2015;33(7):692–700. doi:10.1200/JCO.2014.59.481225605843
   PubMed Web of Science ®Google Scholar
• Yang MJ, Chiu HH, Wang HM, et al. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann Surg Oncol. 2010;17(2):624–633. doi:10.1245/s10434-009-0831-819937133
   PubMed Web of Science ®Google Scholar
• Hyun KA, Koo GB, Han H, et al. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget. 2016;7(17):24677–24687. doi:10.18632/oncotarget.825027013581
   PubMedGoogle Scholar
• Wu F, Zhu J, Mao Y, et al. Associations between the Epithelial-Mesenchymal Transition Phenotypes of Circulating Tumor Cells and the Clinicopathological Features of Patients with Colorectal Cancer. Dis Markers. 2017;2017:9474532. doi:10.1155/2017/947453229430076
   PubMed Web of Science ®Google Scholar
• Liang XF, Shi BZ, Wang K, et al. Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery. Biomaterials. 2016;82:194–207. doi:10.1016/j.biomaterials.2015.12.01526763734
   PubMed Web of Science ®Google Scholar
• Ding J, Wang K, Tang WJ, et al. Construction of Epidermal Growth Factor Receptor Peptide Magnetic Nanovesicles with Lipid Bilayers for Enhanced Capture of Liver Cancer Circulating Tumor Cells. Anal Chem. 2016;88(18):8997–9003. doi:10.1021/acs.analchem.6b0144327558867
   PubMed Web of Science ®Google Scholar
• Liang XF, Li XY, Chang J, et al. Properties and Evaluation of Quaternized Chitosan/Lipid Cation Polymeric Liposomes for Cancer-Targeted Gene Delivery. Langmuir. 2013;29(27):8683–8693. doi:10.1021/la401166v23763489
   PubMed Web of Science ®Google Scholar
• Kondo Y, Hayashi K, Kawakami K, et al. KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer. BMC Cancer. 2017;17(1):311. doi:10.1186/s12885-017-3305-628468669
   PubMed Web of Science ®Google Scholar
• Kuai JH, Wang Q, Zhang AJ, et al. Epidermal growth factor receptor-targeted immune magnetic liposomes capture circulating colorectal tumor cells efficiently. World J Gastroenterol. 2018;24(3):351–359. doi:10.3748/wjg.v24.i3.35129391757
   PubMed Web of Science ®Google Scholar
• Taieb J, Le Malicot K, Shi Q, et al. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. J Natl Cancer Inst. 2017;109.
   Google Scholar
• Musella V, Pietrantonio F, Di Buduo E, et al. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. International Journal of Cancer. 2015;137(6):1467–1474. doi:10.1002/ijc.2949325704501
   PubMed Web of Science ®Google Scholar
• Nicolazzo C, Gradilone A, Carpino G, et al. Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion. Methods Mol Biol. 2019;1884:247–258.30465208
   PubMedGoogle Scholar